Focused ultrasound plus immune therapy for advanced cancer
Part of Cancer clinical trials.
This trial tests a new treatment that combines a special type of focused ultrasound (called histotripsy) with an immune checkpoint inhibitor to boost the immune system's attack on cancer. It is for people with advanced cancer that has not responded to standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer has gotten worse after standard treatments.
- You have a tumor that is close to the skin (within 3 cm) and can be safely treated with a special ultrasound device.
- You have at least one other tumor that can be measured with a scan.
- You are generally in good health (able to do light activities).
- You are willing to have a biopsy of your tumor.
- You can understand Dutch well enough to give informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether a high-intensity focused ultrasound treatment can help people with localized prostate cancer while still avoiding traditional full-dose treatment for some patients. It may be an option for certain intermediate-risk cases where the cancer is confined to the prostate.
This trial tests whether high-intensity focused ultrasound (a targeted heat treatment) can treat some types of breast tumors and potentially reduce the need for more invasive surgery. It may help people who have specific tumor features and who are able to safely undergo MRI and the required positioning.
This trial tests combining a focused ultrasound treatment (high-intensity focused ultrasound) with a new type of hormone therapy for men with advanced prostate cancer that has spread. The goal is to see if this combination can help control the cancer better than hormone therapy alone.
This trial tests a new combination approach for advanced melanoma that is planned for surgical removal. It uses focused ultrasound to heat the tumor, followed by an injection of an experimental immune-stimulating drug (polyICLC), while you continue your standard immunotherapy. The goal is to make the immune system attack the cancer more effectively.
This trial tests a combination of a drug that helps your immune system (adebrelimab) plus chemotherapy, given after a focused ultrasound treatment (HIFU), for women with a specific type of breast cancer (HR+/HER2-) that has not spread beyond the breast or nearby lymph nodes. The goal is to see if this approach can shrink tumors before surgery.
This trial tests whether adding focused ultrasound (HIFU) and an immunotherapy drug (PD-1 inhibitor) before standard chemotherapy can improve outcomes for women with stage II or III triple-negative breast cancer (TNBC). It aims to find a more effective way to shrink tumors before surgery.
Hear when a new Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.